BINV — BioInvent International AB Income Statement
0.000.00%
Last trade - 00:00
- SEK2.84bn
- SEK1.79bn
- SEK71.46m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 93.7 | 147 | 19.4 | 326 | 71.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 232 | 223 | 298 | 377 | 441 |
Operating Profit | -138 | -75.5 | -278 | -50.9 | -370 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -139 | -76.3 | -278 | -42.5 | -330 |
Provision for Income Taxes | |||||
Net Income After Taxes | -139 | -76.3 | -278 | -42.5 | -330 |
Net Income Before Extraordinary Items | |||||
Net Income | -139 | -76.3 | -278 | -42.5 | -330 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -139 | -76.3 | -278 | -42.5 | -330 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.51 | -2.66 | -5.14 | -0.691 | -5.02 |
Dividends per Share |